ライフサイエンスコーパス: continuous positive airway pressure

1 a tracheal pressure control system (5 cm H2O continuous positive airway pressure).

2 The first line of therapy is nasal continuous positive airway pressure.

3 essures that were superimposed on a baseline continuous positive airway pressure.

4 satile perfusion of lungs held motionless by continuous positive airway pressure.

5 IO2 of 0.30 to 0.40 and received 5 cm H2O of continuous positive airway pressure.

6 n treated with supplemental oxygen and nasal continuous positive airway pressure.

7 re and flow-by methods in patients receiving continuous positive airway pressure.

8 th a large increase in the duration of nasal continuous positive airway pressure.

9 +2.3% (9.5) during spontaneous breathing or continuous positive airway pressure.

10 rm babies with a GA less than 34 weeks under continuous positive airway pressure.

11 calculated in the first hours of life under continuous positive airway pressure.

12 n be used for patients who are intolerant to continuous positive airway pressure.

13 lume during pressure support ventilation and continuous positive airway pressure (0.46+/-0.11 L and 0

14 The effect of increased airway pressure (continuous positive airway pressure, 20 cm H2O; n = 12)

15 nditions, animals underwent lung recruitment continuous positive airway pressure 40 cm H2O for 40 sec

16 y pressure preextubation trial (FIO2 = 0.21, continuous positive airway pressure = 5 cm H2O [0.5 kPa]

17 in obese adolescents, a group that has poor continuous positive airway pressure adherence and diffic

18 The old modes of continuous positive airway pressure and bilevel positive

19 Studies show that continuous positive airway pressure and non-invasive pos

20 ew is to summarize the current management of continuous positive airway pressure and noninvasive posi

21 ng respond to surgical treatment, the use of continuous positive airway pressure and noninvasive posi

22 aoperative use of NRS including preinduction continuous positive airway pressure and postextubation N

23 se in mean pulmonary artery pressure in both continuous positive airway pressure and pressure control

24 olume 875 mL, Total Face) were tested during continuous positive airway pressure and pressure support

25 use of positive pressure ventilation (i.e., continuous positive airway pressure and/or intubation).

26 ts were maintained at a therapeutic level of continuous positive airway pressure, and nasal pressure

27 S, indication for ventilation treatment with continuous positive airway pressure, and other potential

28 d substantial lung aeration within 48 hrs of continuous positive airway pressure applied via the endo

29 Subjects were ventilated with continuous positive airway pressure at 5 cm H2O, spontan

30 of children: (1) patients with OSAS without continuous positive airway pressure (CPAP) (n = 13); (2)

31 R(UA) (2.8 +/- 0.3 cmH(2)O l(-1) s; optimal continuous positive airway pressure (CPAP) = 11.3 +/- 0.

32 To determine how long-term treatment with continuous positive airway pressure (CPAP) affects cardi

33 Continuous positive airway pressure (CPAP) and mandibula

34 ine the evidence for and the clinical use of continuous positive airway pressure (CPAP) and positive

35 Data regarding the use of continuous positive airway pressure (CPAP) and recurrenc

36 Mandibular repositioning splints (MRSs) and continuous positive airway pressure (CPAP) are used to t

37 Although continuous positive airway pressure (CPAP) can mitigate

38 Meta-analysis found that continuous positive airway pressure (CPAP) compared with

39 e Sleep Apnea Symptoms Questionnaire (SASQ), continuous positive airway pressure (CPAP) compliance, a

40 The therapeutic and economic benefits of continuous positive airway pressure (CPAP) for moderate

41 an increasingly popular alternative to nasal continuous positive airway pressure (CPAP) for noninvasi

42 t remains unclear whether OSA treatment with continuous positive airway pressure (CPAP) has metabolic

43 d whether oxygen therapy delivered by bubble continuous positive airway pressure (CPAP) improved outc

44 Continuous positive airway pressure (CPAP) in asthma pat

45 Continuous positive airway pressure (CPAP) is considered

46 ing cardiopulmonary resuscitation (CPR), but continuous positive airway pressure (CPAP) is increasing

47 Continuous positive airway pressure (CPAP) is the first-

48 Nasal continuous positive airway pressure (CPAP) is the treatm

49 Continuous positive airway pressure (CPAP) is the treatm

50 Although continuous positive airway pressure (CPAP) is used frequ

51 Continuous positive airway pressure (CPAP) is used to mi

52 sing multiple 3-min 'drops' from therapeutic continuous positive airway pressure (CPAP) levels.

53 Adherence to short-term continuous positive airway pressure (CPAP) may predict l

54 We sought to determine the effect of continuous positive airway pressure (CPAP) of patients w

55 there is little evidence about the effect of continuous positive airway pressure (CPAP) on glycemic c

56 y was to determine the short-term effects of continuous positive airway pressure (CPAP) on sleep-diso

57 d cross-over study of the effects of 4 wk of continuous positive airway pressure (CPAP) or oral place

58 distress syndrome in premature infants with continuous positive airway pressure (CPAP) preserves sur

59 Continuous positive airway pressure (CPAP) reduces blood

60 the influence of lung volume on the level of continuous positive airway pressure (CPAP) required to p

61 Continuous positive airway pressure (CPAP) therapy is th

62 m of this study was to examine the effect of continuous positive airway pressure (CPAP) therapy on at

63 The effects of continuous positive airway pressure (CPAP) therapy on en

64 the influence of spontaneous breathing with continuous positive airway pressure (CPAP) therapy on th

65 Short-term studies indicate that continuous positive airway pressure (CPAP) therapy reduc

66 These patients had been prescribed continuous positive airway pressure (CPAP) therapy to ma

67 Prolonged continuous positive airway pressure (CPAP) therapy with

68 ts were retested after at least two weeks of continuous positive airway pressure (CPAP) therapy.

69 least 1 mo after compliance-monitored nasal continuous positive airway pressure (CPAP) therapy.

70 red from the inspiratory flow contour during continuous positive airway pressure (CPAP) titration in

71 es dead space (V D) and can be combined with continuous positive airway pressure (CPAP) to decrease m

72 tic activity, endothelium, inflammation, and continuous positive airway pressure (CPAP) to identify p

73 s during wakefulness with the application of continuous positive airway pressure (CPAP) to the upper

74 apnea (OSA), the blood pressure response to continuous positive airway pressure (CPAP) treatment is

75 utic and subtherapeutic (0-1 cm H(2)O) nasal continuous positive airway pressure (CPAP) treatment on

76 eart disease (CHD) in women, and the role of continuous positive airway pressure (CPAP) treatment on

77 there is little evidence about the effect of continuous positive airway pressure (CPAP) treatment on

78 ed standardized therapeutic decision-making, continuous positive airway pressure (CPAP) treatment or

79 We tested the hypothesis that long-term continuous positive airway pressure (CPAP) treatment wil

80 pharyngeal sensory evaluation in response to continuous positive airway pressure (CPAP) treatment.

81 We tested the hypothesis that continuous positive airway pressure (CPAP) use and outco

82 extensive noninvasive ventilation (NIV) and continuous positive airway pressure (CPAP) use in patien

83 provements in blood pressure associated with continuous positive airway pressure (CPAP) use, with sma

84 sults from our trial of early treatment with continuous positive airway pressure (CPAP) versus early

85 tained during basal breathing (BB) and nasal continuous positive airway pressure (CPAP) was applied t

86 for this decrement in muscle activity nasal continuous positive airway pressure (CPAP) was applied t

87 herapy has efficacy similar to that of nasal continuous positive airway pressure (CPAP) when used as

88 We delivered continuous positive airway pressure (CPAP) with the helm

89 We aimed to determine if continuous positive airway pressure (CPAP), a form of no

90 n 1.0 mg per liter to receive treatment with continuous positive airway pressure (CPAP), a weight-los

91 First-line treatment for symptomatic OSA is continuous positive airway pressure (CPAP), but its valu

92 retested after 60 d of treatment with nasal continuous positive airway pressure (CPAP), E(max) to br

93 ist control (AC), pressure support (PS), and continuous positive airway pressure (CPAP), separately w

94 odes were eliminated by application of nasal continuous positive airway pressure (CPAP), SPC-muscle a

95 reduction in SNA through the application of continuous positive airway pressure (CPAP), which remain

96 ositive-pressure ventilation (IPPV) or nasal continuous positive airway pressure (CPAP)--at the time

97 were treated only for their SDB, using nasal continuous positive airway pressure (CPAP).

98 during sleep and during application of nasal continuous positive airway pressure (CPAP).

99 ae, in comparison to the standard therapy of continuous positive airway pressure (CPAP).

100 OSA) who were well treated and adherent with continuous positive airway pressure (CPAP).

101 Noninvasive ventilation (continuous positive airway pressure [CPAP] or noninvasiv

102 Afterward, patients were placed on continuous positive airway pressure for 1-2 mins to meas

103 showed that effective treatment of OSA with continuous positive airway pressure for 3 months signifi

104 to maximal airway pressure of 30 cm H2O: 1) continuous positive airway pressure for 30 seconds (CPAP

105 ects of two recruitment maneuvers: 40 cm H2O continuous positive airway pressure for 60 secs and 40 c

106 commonly used as an alternative treatment to continuous positive airway pressure for patients with ob

107 In both the control group and continuous positive airway pressure groups, Pao2 did not

108 tly decreased in OSA patients who adhered to continuous positive airway pressure >/=4 hours daily.

109 High-flow nasal cannula therapy and continuous positive airway pressure had similar efficacy

110 re nonadherent to ventilation treatment with continuous positive airway pressure have an increased ri

111 Nasal continuous positive airway pressure immediately normaliz

112 It remains unclear whether treatment with continuous positive airway pressure improves daytime fun

113 at treatment of obstructive sleep apnea with continuous positive airway pressure improves not only pa

114 advancement device, the main alternative to continuous positive airway pressure, improves endothelia

115 e, and lung function improved after starting continuous positive airway pressure in asthmatics with m

116 , nonadherence to ventilation treatment with continuous positive airway pressure in patients with sev

117 ositive pressure ventilation was superior to continuous positive airway pressure in preventing extuba

118 Data as to the efficacy of continuous positive airway pressure in severe OSA have c

119 Continuous positive airway pressure is a useful second-l

120 Continuous positive airway pressure is the treatment of

121 specialist sleep center; both plans included continuous positive airway pressure, mandibular advancem

122 OSA subjects were treated with continuous positive airway pressure (mean duration of 26

123 f triggering the ventilator while set in the continuous positive airway pressure mode were administer

124 of 2-3 respiratory cycles with supporting a continuous positive airway pressure model.

125 atment of obstructive sleep apnea with nasal continuous positive airway pressure (nasal CPAP) will de

126 Nasal continuous positive airway pressure (NCPAP) is widely us

127 des respiratory support noninferior to nasal continuous positive airway pressure (nCPAP) or bilevel n

128 ) in preterm infants is optimal: noninvasive continuous positive airway pressure (NCPAP) or intubate-

129 If blood pressure can be reduced by nasal continuous positive airway pressure (nCPAP), such treatm

130 The right (control) lung was kept on continuous positive airway pressure of 20 cm H2O, and CO

131 preextubation during airway occlusion and on continuous positive airway pressure of 5 and pressure su

132 h 1 trial supported the beneficial effect of continuous positive airway pressure on quality of life,

133 treatment in the first 72 hours (the use of continuous positive airway pressure or high-flow nasal c

134 dherence is the major obstacle to successful continuous positive airway pressure or noninvasive posit

135 Tidal volume during continuous positive airway pressure or pressure support

136 ive sleep apnea symptoms, adherence to using continuous positive airway pressure, patient satisfactio

137 pressure support ventilation as a 35 cm H2O continuous positive airway pressure period lasting 3-4 s

138 ator support and underwent a 20-min room air-continuous positive airway pressure preextubation trial

139 into four classes: spontaneous breathing or continuous positive airway pressure; pressure support ve

140 Although regulated continuous positive airway pressure, pulse oximeters, an

141 ase in cardiac output immediately after some continuous positive airway pressure recruitment maneuver

142 ve spirometry, deep breathing exercises, and continuous positive airway pressure) reduce pulmonary ri

143 Continuous positive airway pressure reduced extubation f

144 ntilatory failure during a room air-5 cm H2O continuous positive airway pressure, spontaneous breathi

145 racheal pressure triggering of a demand-flow continuous positive airway pressure system creates an ef

146 ork per liter of ventilation measured during continuous positive airway pressure, T piece, or pressur

147 at birth toward more aggressive use of nasal continuous positive airway pressure, the optimal timing

148 Continuous positive airway pressure, the treatment of ch

149 In OSA patients, continuous positive airway pressure therapy resulted in

150 After 4 weeks of continuous positive airway pressure therapy, flow-mediat

151 pnea syndrome who are regular users of nasal continuous positive airway pressure therapy.

152 time sleepiness despite regular use of nasal continuous positive airway pressure therapy.

153 the use of stimulant medications or empiric continuous positive airway pressure to reduce driving ri

154 was made for treatment of confirmed OSA with continuous positive airway pressure to reduce driving ri

155 Traits were measured by repeatedly lowering continuous positive airway pressure to subtherapeutic le

156 onchus for lung isolation and application of continuous positive airway pressure to the left lung for

157 RECOMMENDATION 2: ACP recommends continuous positive airway pressure treatment as initial

158 ncement devices as an alternative therapy to continuous positive airway pressure treatment for patien

159 Continuous positive airway pressure treatment improves t

160 Continuous positive airway pressure treatment was associ

161 Patients who received continuous positive airway pressure treatment were signi

162 ated OSA, and in the morning after effective continuous positive airway pressure treatment.

163 r those with adverse effects associated with continuous positive airway pressure treatment.

164 were randomized to 8 weeks of active or sham continuous positive airway pressure treatment.

165 s in the sham arm received 8 weeks of active continuous positive airway pressure treatment.

166 ggest a role for high-flow nasal cannula and continuous positive airway pressure use in a monitored s

167 was to assess the effects of treatment with continuous positive airway pressure versus conservative

168 t the need for randomized clinical trials of continuous positive airway pressure versus mechanical ve

169 recommended for narcolepsy and hypersomnia; continuous positive airway pressure, weight loss, surger

170 Nasal continuous positive airway pressure when OSAS was diagno

171 Although most infants were ventilated, continuous positive airway pressure without ventilation